We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Mathew Maurer

Mathew S. Maurer MD

Arnold and Arlene Goldstein Professor of Cardiology; Professor of Medicine; Director, Clinical Cardiovascular Research Laboratory for the Elderly; Director, Cardiac Amyloidosis Program, Columbia University Irving Medical Center, New York Presbyterian Hospital – Columbia Campus, New York, New York

Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation.  He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus. 

He has published over 300 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy.   Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults. 

Disclosures

Dr. Maurer receives grant support from NIH R01HL139671, R21AG058348, and K24AG036778; consulting income from Pfizer, Eidos, Prothena, Akcea and Alnylam, Intellia, GSK; and institutional support in the form of clinical trial funding from Pfizer, Prothena, Eidos and Alnylam.